<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30076657</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1349-7006</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>109</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer science</Title>                <ISOAbbreviation>Cancer Sci.</ISOAbbreviation>            </Journal>            <ArticleTitle>STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>3305-3315</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.13761</ELocationID>            <Abstract>                <AbstractText>Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that has been approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Despite the remarkable efficacy of T-DM1 in many patients, resistance to this therapeutic has emerged as a significant clinical problem. In the current study, we used BT-474/KR cells, a T-DM1-resistant cell line established from HER2-positive BT-474 breast cancer cells, as a model to investigate mechanisms of T-DM1 resistance and explore effective therapeutic regimens. We show here for the first time that activation of signal transducer and activator of transcription 3 (STAT3) mediated by leukemia inhibitory factor receptor (LIFR) overexpression confers resistance to T-DM1. Moreover, secreted factors induced by activated STAT3 in resistant cells limit the responsiveness of cells that were originally sensitive to T-DM1. Importantly, STAT3 inhibition sensitizes resistant cells to T-DM1, both in vitro and in vivo, suggesting that the combination T-DM1 with STAT3-targeted therapy is a potential treatment for T-DM1-refractory patients.</AbstractText>                <CopyrightInformation>Â© 2018 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Lei</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Quanren</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gao</LastName>                    <ForeName>Mingzhao</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fu</LastName>                    <ForeName>Li</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yun</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Quan</LastName>                    <ForeName>Haitian</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lou</LastName>                    <ForeName>Liguang</ForeName>                    <Initials>L</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7396-7122</Identifier>                    <AffiliationInfo>                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>14DZ2294100</GrantID>                    <Agency>Science and Technology Commission of Shanghai Municipality</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>81502636</GrantID>                    <Agency>National Natural Science Foundation of China</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>31</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cancer Sci</MedlineTA>            <NlmUniqueID>101168776</NlmUniqueID>            <ISSNLinking>1347-9032</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C507840">LIFR protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D053680">Leukemia Inhibitory Factor Receptor alpha Subunit</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>14083FR882</RegistryNumber>                <NameOfSubstance UI="D008453">Maytansine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P188ANX8CK</RegistryNumber>                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>SE2KH7T06F</RegistryNumber>                <NameOfSubstance UI="C550911">ado-trastuzumab emtansine</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cytokine Growth Factor Rev. 2015 Oct;26(5):533-44</RefSource>                <PMID Version="1">26187859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2018 Oct;109(10):3305-3315</RefSource>                <PMID Version="1">30076657</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochim Biophys Acta. 2016 Apr;1865(2):255-65</RefSource>                <PMID Version="1">26993403</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2008 Apr 15;122(8):1730-7</RefSource>                <PMID Version="1">18074350</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Bioenerg Biomembr. 2007 Dec;39(5-6):481-7</RefSource>                <PMID Version="1">18058211</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2009 Nov;9(11):798-809</RefSource>                <PMID Version="1">19851315</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol Pract. 2018 Aug;14(8):501-504</RefSource>                <PMID Version="1">29989839</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Biol Macromol. 2018 Oct 1;117:993-1001</RefSource>                <PMID Version="1">29782972</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2013 Sep 19;501(7467):328-37</RefSource>                <PMID Version="1">24048065</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2018 Feb 28;9(21):15721-15731</RefSource>                <PMID Version="1">29644004</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Res Rev. 2012 Nov;32(6):1220-62</RefSource>                <PMID Version="1">21374643</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2003 Jun 2;88(11):1721-6</RefSource>                <PMID Version="1">12771987</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Oncol. 2014 Feb;44(2):403-11</RefSource>                <PMID Version="1">24297508</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2017 Jan 15;23(2):503-513</RefSource>                <PMID Version="1">27435393</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Oncol Hematol. 2016 Jan;97:96-106</RefSource>                <PMID Version="1">26318092</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44</RefSource>                <PMID Version="1">25605917</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2018 Jun;67:10-20</RefSource>                <PMID Version="1">29751334</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2017 Feb 1;23(3):636-648</RefSource>                <PMID Version="1">27698002</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Oncol. 2000 Dec;27(6 Suppl 11):38-45; discussion 92-100</RefSource>                <PMID Version="1">11236027</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2018 Mar;37(10):1354-1368</RefSource>                <PMID Version="1">29269867</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>MAbs. 2013 Jan-Feb;5(1):13-21</RefSource>                <PMID Version="1">23221464</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2016 Sep 12;30(3):459-473</RefSource>                <PMID Version="1">27622335</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2016 Sep;37(9):11553-11572</RefSource>                <PMID Version="1">27260630</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Univ Mariae Curie Sklodowska Med. 2004;59(2):189-93</RefSource>                <PMID Version="1">16146075</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2014 Mar 05;16(2):209</RefSource>                <PMID Version="1">24887180</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Nov 15;68(22):9280-90</RefSource>                <PMID Version="1">19010901</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 1998 Nov;34(12):1958-61</RefSource>                <PMID Version="1">10023322</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 1992 May 25;267(15):10238-47</RefSource>                <PMID Version="1">1587813</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2017 Jul;108(7):1458-1468</RefSource>                <PMID Version="1">28388007</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2012 Aug 24;47(4):570-84</RefSource>                <PMID Version="1">22819326</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2014 Nov;14(11):736-46</RefSource>                <PMID Version="1">25342631</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2017 Sep 1;77(17):4639-4651</RefSource>                <PMID Version="1">28687619</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2015 Apr 27;10(4):e0123958</RefSource>                <PMID Version="1">25915540</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2006 Apr 15;66(8):4426-33</RefSource>                <PMID Version="1">16618769</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acc Chem Res. 2008 Jan;41(1):98-107</RefSource>                <PMID Version="1">17705444</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2003 Oct 20;22(47):7468-85</RefSource>                <PMID Version="1">14576852</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Med. 2015 Aug 03;13:177</RefSource>                <PMID Version="1">26234940</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Lett. 2012 Nov 1;324(1):75-82</RefSource>                <PMID Version="1">22579805</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2010 Dec 15;127(12):2893-917</RefSource>                <PMID Version="1">21351269</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Oct;153(3):493-505</RefSource>                <PMID Version="1">26400847</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2008 Oct;13(10):1114-9</RefSource>                <PMID Version="1">18849320</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gene. 2016 Jun 10;584(1):75-82</RefSource>                <PMID Version="1">26976343</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2011 Jul;128(2):347-56</RefSource>                <PMID Version="1">20730488</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2011 Mar 11;286(10):7797-811</RefSource>                <PMID Version="1">21193402</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D053680" MajorTopicYN="N">Leukemia Inhibitory Factor Receptor alpha Subunit</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008453" MajorTopicYN="N">Maytansine</DescriptorName>                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">STAT3</Keyword>            <Keyword MajorTopicYN="N">drug resistance</Keyword>            <Keyword MajorTopicYN="N">leukemia inhibitory factor receptor</Keyword>            <Keyword MajorTopicYN="N">secreted factor</Keyword>            <Keyword MajorTopicYN="N">trastuzumab-emtansine</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30076657</ArticleId>            <ArticleId IdType="doi">10.1111/cas.13761</ArticleId>            <ArticleId IdType="pmc">PMC6172075</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>